Kaplan-Meier curves of patient fractions remaining without final normalization of platelet count (>150 × 109/L) after the start of caplacizumab treatment.
Figure 3.

Kaplan-Meier curves of patient fractions remaining without final normalization of platelet count (>150 × 109/L) after the start of caplacizumab treatment.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal